Factorial Partners LLC Has $5.60 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Factorial Partners LLC grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 14.3% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 311,000 shares of the company’s stock after acquiring an additional 39,000 shares during the period. Teva Pharmaceutical Industries makes up approximately 3.2% of Factorial Partners LLC’s portfolio, making the stock its 3rd biggest position. Factorial Partners LLC’s holdings in Teva Pharmaceutical Industries were worth $5,604,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Coronation Fund Managers Ltd. bought a new position in Teva Pharmaceutical Industries during the 2nd quarter worth $1,334,000. Point72 Asset Management L.P. raised its position in shares of Teva Pharmaceutical Industries by 38.0% during the second quarter. Point72 Asset Management L.P. now owns 1,319,217 shares of the company’s stock worth $21,437,000 after acquiring an additional 363,217 shares during the last quarter. Lighthouse Investment Partners LLC acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $6,825,000. Ritholtz Wealth Management lifted its position in shares of Teva Pharmaceutical Industries by 269.5% during the 3rd quarter. Ritholtz Wealth Management now owns 41,643 shares of the company’s stock valued at $750,000 after acquiring an additional 30,374 shares during the period. Finally, Diversify Wealth Management LLC bought a new position in Teva Pharmaceutical Industries during the third quarter worth $640,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TEVA has been the subject of several research analyst reports. Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Trading Up 1.9 %

Shares of Teva Pharmaceutical Industries stock opened at $16.80 on Wednesday. The firm has a market cap of $19.03 billion, a PE ratio of -19.76, a P/E/G ratio of 1.28 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a 1 year low of $9.04 and a 1 year high of $19.31. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The stock has a fifty day moving average price of $17.75 and a 200-day moving average price of $17.28.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.